PLASMA CELL LEUKEMIA
Clinical trials for PLASMA CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new PLASMA CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for PLASMA CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug may reduce dangerous side effects of stem cell transplants in older patients
Disease control OngoingThis early-phase study tests whether the drug itacitinib can prevent cytokine release syndrome (a severe inflammatory reaction) and reduce the need for long-term immune-suppressing medications after a stem cell transplant. The trial involves 32 older adults (age 60+) with certain…
Matched conditions: PLASMA CELL LEUKEMIA
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 01, 2026 15:39 UTC
-
Multiple myeloma drug study canceled before it began
Knowledge-focused TerminatedThis study was designed to find the safest dose of the chemotherapy drug bendamustine for people with multiple myeloma that had not been cured by earlier treatments. The trial was withdrawn before any participants were enrolled, so no results are available. The goal was to unders…
Matched conditions: PLASMA CELL LEUKEMIA
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:50 UTC
-
Lab tests aim to match myeloma patients with best drugs
Knowledge-focused OngoingThis study tests a new way to choose treatments for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to therapy. Researchers use a lab test that checks many drugs at once, along with genetic information, to find which drugs might work b…
Matched conditions: PLASMA CELL LEUKEMIA
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:49 UTC